A Phase I study of ISIS-PKKRx for the treatment of hereditary angioedema (HAE)
Phase of Trial: Phase I
Latest Information Update: 24 Feb 2015
Price : $35 *
At a glance
- Drugs IONIS PKKRx (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions; First in man
- Sponsors Isis Pharmaceuticals
- 24 Feb 2015 Results published in an Isis Pharmaceuticals media release.
- 24 Feb 2015 Status changed from recruiting to completed, as reported in an Isis Pharmaceuticals media release.
- 16 Sep 2014 New trial record